Tomer lab maps impact of Ketamine on brain-wide neural circuits

December 04, 2023

The Tomer Lab has published a report detailing the first-ever high-resolution mapping of the structural impact of ketamine on brain-wide neural circuits. Ketamine, a dissociative anesthetic clinically used for over five decades, is increasingly being tested for treating various neurological disorders, including its transformative, fast-acting use as an antidepressant. However, ketamine's antidepressant effects are known to be transient, lasting about a week. This necessitates long-term maintenance treatment. Such prolonged use poses significant risks for side effects, which are not well studied.

The Tomer Lab systematically investigated ketamine's structural impact on the brain-wide dopamine system in mice across a range of doses. Their study revealed a widespread, non-uniform impact of ketamine across the entire brain and supported a role for translational regulations in affecting these structural changes. In general, the study demonstrates that the same neuron types in different brain regions can respond differently to the same drug, underscoring the importance of developing targeted drug delivery approaches for neurological disorders. Furthermore, the study introduces efficient tools for systematic, unbiased brain-wide mapping of various drugs' effects on the brain at a sub-cellular level. For more detailed information, please refer to the following link: https://www.cell.com/cell-reports/fulltext/S2211-1247(23)01503-6